I did write
a post a while back highlighting an excellent on line resource that gives
clinicians data on 81 treatable forms of Intellectual Disability, ID (formerly
known as mental retardation, MR).
There is a
big overlap between the causes of some ID and causes of some autism.
If you have
a case of autism, it is worth reviewing the 81 treatable forms of ID, just in
case you have one, even a mild version causing minimal ID. Partial dysfunctions certainly are possible, as we saw with biotin.
It is also
very interesting to look through the therapies used and see how they overlap
with those used by people in their n=1 case of autism.
For example the therapy for SLOS (Smith–Lemli–Opitz
syndrome) which is related to very low cholesterol is to give cholesterol and
Simvastatin. Simvastatin is widely used
in older people to LOWER cholesterol. Statins have several other known modes of action. We use Atorvastatin.
Note all the vitamin related syndromes etc.
The data is
all on the online resource that is highlighted at the top of every page in this
blog, but as one regular reader from Hong Kong pointed out, it is better to actually read it in
table form.
He recommended the two
papers below. I reproduced some of the
tables, but I suggest you click the link to read the papers.
The formatting is not so good, since I have cut and paste from the papers.
You have the syndromes, their therapies and their diagnostic tests.
Complicated questions should be addressed to the authors of the papers or your doctor.
Table 2Overview of all 81
treatable IDs.In this table, the IEMs are grouped according to the
biochemical phenotype as presented in standard textbooks, and alphabetically.
Of note, primary CoQ deficiency was considered as one single IEM even though
more though 6 genes have been described; this is true as well for MELAS and
Pyruvate Dehydrogenase Complex deficiency.
|
||||
Biochemical category
|
Disease name
|
OMIM#
|
Biochemical deficiency
|
Gene(s)
|
Amino acids
|
HHH syndrome (hyperornithinemia, hyperammonemia,
homocitrullinemia)
|
238970
|
Ornithine translocase
|
SLC25A15 (AR)
|
l.o. Non-ketotic hyperglycinemia
|
605899
|
Aminomethyltransferase/glycine decarboxylase/glycine cleavage
system H protein
|
AMT/GLDC/GCSH (AR)
|
|
Phenylketonuria
|
261600
|
Phenylalanine hydroxylase
|
PAH (AR)
|
|
PHGDH deficiency(Serine deficiency)
|
601815
|
Phosphoglycerate dehydrogenase
|
PHGDH (AR)
|
|
PSAT deficiency(Serine deficiency)
|
610992
|
Phosphoserine aminotransferase
|
PSAT1 (AR)
|
|
PSPH deficiency(Serine deficiency)
|
614023
|
Phosphoserine phosphatase
|
PSPH (AR)
|
|
Tyrosinemia type II
|
276600
|
Cytosolic tyrosine aminotransferase
|
TAT (AR)
|
|
Cholesterol & bile acids
|
Cerebrotendinous xanthomatosis
|
213700
|
Sterol-27-hydroxylase
|
CYP27A1 (AR)
|
Smith–Lemli–Opitz Syndrome
|
270400
|
7-Dehydroxycholesterol reductase
|
DHCR7 (AR)
|
|
Creatine
|
AGAT deficiency
|
612718
|
Arginine: glycine amidinotransferase
|
GATM (AR)
|
Creatine transporter Defect
|
300352
|
Creatine transporter
|
SLC6A8 (X-linked)
|
|
GAMT deficiency
|
612736
|
Guanidino-acetate-N-methyltransferase
|
GAMT (AR)
|
|
Fatty aldehydes
|
Sjögren–Larsson syndrome
|
270200
|
Fatty aldehyde dehydrogenase
|
ALDH3A2 (AR)
|
Glucose transport & regulation
|
GLUT1 deficiency syndrome
|
606777
|
Glucose transporter blood–brain barrier
|
SLC2A1 (AR)
|
Hyperinsulinism hyperammonemia syndrome
|
606762
|
Glutamate dehydrogenase superactivity
|
GLUD1 (AR)
|
|
Hyperhomocysteinemia
|
Cobalamin C deficiency
|
277400
|
Methylmalonyl-CoA mutase and homocysteine :
methyltetrahydrofolate methyltransferase
|
MMACHC (AR)
|
Cobalamin D deficiency
|
277410
|
C2ORF25 protein
|
MMADHC (AR)
|
|
Cobalamin E deficiency
|
236270
|
Methionine synthase reductase
|
MTRR (AR)
|
|
Cobalamin F deficiency
|
277380
|
Lysosomal cobalamin exporter
|
LMBRD1 (AR)
|
|
Cobalamin G deficiency
|
250940
|
5-Methyltetrahydrofolate-homocysteine S-methyltransferase
|
MTR (AR)
|
|
Homocystinuria
|
236200
|
Cystathatione β-synthase
|
CBS (AR)
|
|
l.o. MTHFR deficiency
|
236250
|
Methylenetetrahydrofolate reductase deficiency
|
MTHFR (AR)
|
|
Lysosomes
|
α-Mannosidosis
|
248500
|
α-Mannosidase
|
MAN2B1 (AR)
|
Aspartylglucosaminuria
|
208400
|
Aspartylglucosaminidase
|
AGA (AR)
|
|
Gaucher disease type III
|
231000
|
ß-Glucosidase
|
GBA (AR)
|
|
Hunter syndrome (MPS II)
|
309900
|
Iduronate-2-sulfatase
|
IDS (X-linked)
|
|
Hurler syndrome (MPS I)
|
607014
|
α-L-iduronidase
|
IDUA (AR)
|
|
l.o. Metachromatic leukodystrophy
|
250100
|
Arylsulfatase A
|
ARSA (AR)
|
|
Niemann–Pick disease type C
|
257220
|
Intracellular transport cholesterol & sphingosines
|
NPC1 NPC2 (AR)
|
|
Sanfilippo syndrome A (MPS IIIa)
|
252900
|
Heparan-N-sulfatase
|
SGSH (AR)
|
|
Sanfilippo syndrome B (MPS IIIb)
|
252920
|
N-acetyl-glucosaminidase
|
NAGLU (AR)
|
|
Sanfilippo syndrome C (MPS IIIc)
|
252930
|
Acetyl-CoA glucosamine-N-acetyl transferase
|
HGSNAT (AR)
|
|
Sanfilippo syndrome D (MPS IIId)
|
252940
|
N-acetyl-glucosamine-6-Sulfatase
|
GNS (AR)
|
|
Sly syndrome (MPS VII)
|
253220
|
β-glucuronidase
|
GUSB (AR)
|
|
Metals
|
Aceruloplasminemia
|
604290
|
Ceruloplasmin (iron homeostasis)
|
CP (AR)
|
Menkes disease/Occipital horn syndrome
|
304150
|
Copper transport protein (efflux from cell)
|
ATP7A (AR)
|
|
Wilson disease
|
277900
|
Copper transport protein (liver to bile)
|
ATP7B (AR)
|
|
Mitochondria
|
Co enzyme Q10 deficiency
|
607426
|
Coenzyme Q2 or mitochondrial
parahydroxybenzoate-polyprenyltransferase; aprataxin; prenyl diphosphate
synthase subunit 1; prenyl diphosphate synthase subunit 2; coenzyme Q8;
coenzyme Q9
|
COQ2, APTX, PDSS1, PDSS2, CABC1, COQ9 (most AR)
|
MELAS
|
540000
|
Mitochondrial energy deficiency
|
MTTL1, MTTQ,MTTH, MTTK,MTTC, MTTS1,MTND1, MTND5,MTND6, MTTS2
(Mt)
|
|
PDH complex deficiency
|
OMIM# according to each enzyme subunit deficiency: 312170;
245348; 245349
|
Pyruvate dehydrogenase complex (E1α, E2, E3)
|
PDHA1 (X-linked), DLAT (AR), PDHX (AR)
|
|
Neurotransmission
|
DHPR deficiency (biopterin deficiency)
|
261630
|
Dihydropteridine reductase
|
QDPR (AR)
|
GTPCH1 deficiency (biopterin deficiency)
|
233910
|
GTP cyclohydrolase
|
GCH1 (AR)
|
|
PCD deficiency (biopterin deficiency)
|
264070
|
Pterin-4α-carbinolamine dehydratase
|
PCBD1 (AR)
|
|
PTPS deficiency (biopterin deficiency)
|
261640
|
6-Pyruvoyltetrahydropterin synthase
|
PTS (AR)
|
|
SPR deficiency (biopterin deficiency)
|
612716
|
Sepiapterin reductase
|
SPR (AR)
|
|
SSADH deficiency
|
271980
|
Succinic semialdehyde dehydrogenase
|
ALDH5A1 (AR)
|
|
Tyrosine Hydroxylase Deficiency
|
605407
|
Tyrosine Hydroxylase
|
TH (AR)
|
|
Organic acids
|
3-Methylcrotonyl glycinuria
|
GENE OMIM # 210200; 210210
|
3-Methylcrotonyl CoA carboxylase (3-MCC)
|
MCC1/MCC2 (AR)
|
3-Methylglutaconic aciduria type I
|
250950
|
3-Methylglutaconyl-CoA hydratase
|
AUH (AR)
|
|
β-Ketothiolase deficiency
|
203750
|
Mitochondrial acetoacetyl-CoA thiolase
|
ACAT1 (AR)
|
|
Cobalamin A deficiency
|
251100
|
MMAA protein
|
MMAA (AR)
|
|
Cobalamin B deficiency
|
251110
|
Cob(I)alamin adenosyltransferase
|
MMAB (AR)
|
|
Ethylmalonic encephalopathy
|
602473
|
Mitochondrial sulfur dioxygenase
|
ETHE1 (AR)
|
|
l.o. Glutaric acidemia I
|
231670
|
Glutaryl-CoA dehydrogenase
|
GCDH (AR)
|
|
Glutaric acidemia II
|
231680
|
Multiple acyl-CoA dehydrogenase
|
ETFA, ETFB,ETFDH (AR)
|
|
HMG-CoA lyase deficiency
|
246450
|
3-Hydroxy-3-methylglutaryl-CoA lyase
|
HMGCL (AR)
|
|
l.o. Isovaleric acidemia
|
243500
|
Isovaleryl-CoA dehydrogenase
|
IVD (AR)
|
|
Maple syrup urine disease (variant)
|
248600
|
Branched-chain 2-ketoacid complex
|
BCKDHA/BCKDHB/ DBT (AR)
|
|
l.o. Methylmalonic acidemia
|
251000
|
Methylmalonyl-CoA mutase
|
MUT (AR)
|
|
MHBD deficiency
|
300438
|
2-Methyl-3-hydroxybutyryl-CoA dehydrogenase
|
HSD17B10 (X-linked recessive)
|
|
mHMG-CoA synthase deficiency
|
605911
|
Mitochondrial 3-hydroxy-3-Methylglutaryl-CoA synthase
|
HMGCS2 (AR)
|
|
l.o. Propionic acidemia
|
606054
|
Propionyl-CoA carboxylase
|
PCCA/PCCB (AR)
|
|
SCOT deficiency
|
245050
|
Succinyl-CoA 3-oxoacid CoA transferase
|
OXCT1 (AR)
|
|
Peroxisomes
|
X-linked adrenoleukodystrophy
|
300100
|
Peroxisomal transport membrane protein ALDP
|
ABCD1 (X-linked)
|
Pyrimidines
|
Pyrimidine 5-nucleotidase superactivity
|
GENE OMIM # 606224
|
Pyrimidine-5-nucleotidase Superactivity
|
NT5C3 (AR)
|
Urea cycle
|
l.o. Argininemia
|
207800
|
Arginase
|
ARG1 (AR)
|
l.o. Argininosuccinic aciduria
|
207900
|
Argininosuccinate lyase
|
ASL (AR)
|
|
l.o. Citrullinemia
|
215700
|
Argininosuccinate Synthetase
|
ASS1 (AR)
|
|
Citrullinemia type II
|
605814
|
Citrin (aspartate–glutamate carrier)
|
SLC25A13
|
|
l.o. CPS deficiency
|
237300
|
Carbamoyl phosphate synthetase
|
CPS1 (AR)
|
|
l.o. NAGS deficiency
|
237310
|
N-acetylglutamate synthetase
|
NAGS (AR)
|
|
l.o. OTC Deficiency
|
311250
|
Ornithine transcarbamoylase
|
OTC (X-linked)
|
|
Vitamins/co-factors
|
Biotinidase deficiency
|
253260
|
Biotinidase
|
BTD (AR)
|
Biotin responsive basal ganglia disease
|
607483
|
Biotin transport
|
SLC19A3(AR)
|
|
Cerebral folate receptor-α deficiency
|
613068
|
a.o. Cerebral folate transporter
|
FOLR1 (AR)
|
|
Congenital intrinsic factor deficiency
|
261000
|
Intrinsic factor deficiency
|
GIF (AR)
|
|
Holocarboxylase synthetase deficiency
|
253270
|
Holocarboxylase synthetase
|
HLCS (AR)
|
|
Imerslund Gräsbeck syndrome
|
261100
|
IF-Cbl receptor defects (cubulin/amnionless)
|
CUBN & AMN (AR)
|
|
Molybdenum co-factor deficiency type A
|
252150
|
Sulfite oxidase & xanthine dehydrogenase & aldehyde
oxidase
|
MOCS1, MOCS2,(AR)
|
|
Pyridoxine dependent epilepsy
|
266100
|
Pyridoxine phosphate oxidase
|
ALDH7A1 (AR),
|
|
Thiamine responsive encephalopathy
|
606152
|
Thiamine transport
|
SLC19A3 (AR)
|
Table 5Overview of all causal therapies (n=91).This Table provides an
overview of the specific therapy/-ies available for each IEM with relevant
level(s) of evidence, therapeutic effect(s) on primary and/or secondary
outcomes and use in clinical practice. For 10 IEMs, two therapies are
available; these are listed separately (in brackets).
|
|||||
Disease name
|
Therapeutic modality (−ies)
|
Level of evidence
|
Clinical practice
|
Treatment effect
|
Literature references
|
Aceruloplasminemia
|
Iron chelation
|
4
|
Standard of care
|
D,E
|
|
(X-linked)adrenoleukodystrophy
|
Stemcell transplantation (Gene
therapy)
|
1c (5)
|
Individual basis (Individual basis)
|
D,E (D,E)
|
|
AGAT deficiency
|
Creatine supplements
|
4
|
Standard of care
|
A,D
|
|
α-Mannosidosis
|
Haematopoietic stem cell
transplantation
|
4-5
|
Individual basis
|
D
|
[54
|
l.o. Argininemia
|
Dietary protein restriction, arginine
supplement, sodium benzoate, phenylbutyrate (Liver transplantation)
|
2b (4)
|
Standard of care (Individual basis)
|
B,C,D,E,F,G (C)
|
|
l.o. Argininosuccinic aciduria
|
Dietary protein restriction, arginine
supplement, sodium benzoate, phenylbutyrate (liver transplantation)
|
2b (4)
|
Standard of care (individual basis)
|
B,C,D,E,F,G (C)
|
|
Aspartylglucosaminuria
|
Haematopoietic stem cell
transplantation
|
4-5
|
Individual basis
|
D
|
[62
|
β-Ketothiolase deficiency
|
Avoid fasting, sickday management,
protein restriction
|
5
|
Standard of care
|
C
|
|
Biotin responsive basal ganglia
disease
|
Biotin supplement
|
4
|
Standard of care
|
A,E
|
[66
|
Biotinidase deficiency
|
Biotin supplement
|
2c
|
Standard of care
|
A,E,G
|
[67
|
Cerebral folate receptor-α deficiency
|
Folinic acid
|
4
|
Standard of care
|
A,D,E,F
|
|
Cerebrotendinous xanthomatosis
|
Chenodesoxycholic acid, HMG reductase
inhibitor
|
4
|
Standard of care
|
B,D,E,G
|
|
l.o. Citrullinemia
|
Dietary protein restriction, arginine
supplement, sodium benzoate, phenylbutyrate (Liver transplantation)
|
2b (4)
|
Standard of care (Individual basis)
|
B,C,D,E,F,G (C)
|
|
Citrullinemia type II
|
Dietary protein restriction, arginine
supplement, sodium benzoate, phenylbutyrate (Liver transplantation)
|
2b (4)
|
Standard of care (Individual basis)
|
B,C,D,E,F,G (C)
|
|
Co enzyme Q10 deficiency
|
CoQ supplements
|
4
|
Standard of care
|
E,F
|
|
Cobalamin A deficiency
|
Hydroxycobalamin, protein restriction
|
4
|
Standard of care
|
C,G
|
|
Cobalamin B deficiency
|
Hydroxycobalamin, protein restriction
|
4
|
Standard of care
|
C,G
|
|
Cobalamin C deficiency
|
Hydroxycobalamin
|
4
|
Standard of care
|
C,D,G
|
|
Cobalamin D deficiency
|
Hydroxy-/cyanocobalamin
|
4
|
Standard of care
|
C,D,G
|
|
Cobalamin E deficiency
|
Hydroxy-/methylcobalamin, betaine
|
4
|
Standard of care
|
C,D,G
|
|
Cobalamin F deficiency
|
Hydroxycobalamin
|
4
|
Standard of care
|
C,D,G
|
|
Cobalamin G deficiency
|
Hydroxy-/methylcobalamin, betaine
|
4
|
Standard of care
|
C,D,G
|
|
Congenital intrinsic factor
deficiency
|
Hydroxycobalamin
|
4
|
Standard of care
|
A,E,G
|
[80
|
l.o. CPS deficiency
|
Dietary protein restriction, arginine
supplement, sodium benzoate, phenylbutyrate (Liver transplantation)
|
2b & 4
|
Standard of care (Individual basis)
|
B,C,D,E,F,G (C)
|
|
Creatine transporter defect
|
Creatine, glycine, arginine supplements
|
4-5
|
Individual basis
|
F
|
[29
|
DHPR deficiency
|
BH4,diet, amine replacement, folinic
acid
|
4
|
Standard of care
|
A,E
|
[52
|
Ethylmalonic encephalopathy
|
N-acetylcysteine, oral metronidazol
|
4
|
Standard of care
|
E,G
|
[81
|
GAMT deficiency
|
Arginine restriction, creatine &
ornithine supplements
|
4
|
Standard of care
|
B,D,E,F
|
|
Gaucher disease type III
|
Haematopoietic stem cell
transplantation
|
4–5
|
Individual basis
|
D,G
|
|
GLUT1 deficiency syndrome
|
Ketogenic diet
|
4
|
Standard of Care
|
F
|
|
l.o. Glutaric acidemia I
|
Lysine restriction, carnitine
supplements
|
2c
|
Standard of care
|
C,D,E,G
|
|
Glutaric acidemia II
|
Carnitine, riboflavin,
β-hydroxybutyrate supplements; sick day management
|
5
|
Standard of care
|
C,G
|
|
GTPCH1 deficiency
|
BH4, amine replacement
|
4
|
Standard of care
|
A,E
|
[91
|
HHH syndrome
|
Dietary protein restriction,
ornithine supplement, sodium benzoate, phenylacetate
|
4
|
Standard of care
|
B,C,D,E,F,G
|
[92
|
HMG-CoA lyase deficiency
|
Protein restriction, avoid fasting,
sick day management,
|
5
|
Standard of care
|
C
|
|
Holocarboxylase synthetase deficiency
|
Biotin supplement
|
4
|
Standard of care
|
A,E,G
|
|
Homocystinuria
|
Methionine restriction, +/−pyridoxine,
+/−betaine
|
2c
|
Standard of care
|
C,D,G
|
|
Hunter syndrome (MPS II)
|
Haematopoietic stem cell
transplantation
|
4–5
|
Individual basis
|
D,G
|
|
Hurler syndrome (MPS I)
|
Haematopoietic stem cell
transplantation
|
1c
|
Standard of care
|
D,G
|
|
Hyperammonemia–Hyperinsulinism
syndrome
|
Diazoxide
|
4–5
|
Standard of care
|
D
|
|
Imerslund Gräsbeck syndrome
|
Hydroxycobalamin
|
4
|
Standard of Care
|
A,E,G
|
[100
|
l.o. Isovaleric acidemia
|
Dietary protein restriction,
carnitine supplements, avoid fasting, sick day management
|
2c
|
Standard of care
|
C,G
|
|
l.o. NAGS deficiency
|
Dietary protein restriction, arginine
supplement, sodium benzoate, phenylbutyrate (Liver transplantation)
|
2b & 4
|
Standard of care (Individual basis)
|
B,C,D,E,F,G (C)
|
|
l.o. Non-ketotic hyperglycinemia
|
Glycine restriction; +/−sodium
benzoate, NMDA receptor antagonists, other neuromodulating agents
|
4-5
|
Standard of Care
|
B,D,E,F
|
[106
|
Maple syrup urine disease (variant)
|
Dietary restriction branched
amino-acids, avoid fasting, (Liver transplantation)
|
4 & 4
|
Standard of care (Individual basis)
|
B,C,D (A,C)
|
|
MELAS
|
Arginine supplements
|
4–5
|
Standard of Care
|
C,D,E,F
|
[26
|
Menkes disease occipital horn
syndrome
|
Copper histidine
|
4
|
Individual basis
|
D
|
|
l.o. Metachromatic leukodystrophy
|
Haematopoietic stem cell
transplantation
|
4-5
|
Individual basis
|
D
|
|
3-Methylcrotonyl glycinuria
|
Dietary protein restriction;
carnitine, glycine, biotin supplements; avoid fasting; sick day management
|
5
|
Standard of care
|
C
|
|
3-Methylglutaconic aciduria type I
|
Carnitine Supplements, Avoid Fasting,
Sick Day Management
|
5
|
Standard of care
|
C
|
[117
|
l.o. Methylmalonic acidemia
|
Dietary protein restriction,
carnitine supplements, avoid fasting, sick day management
|
2c
|
Standard of care
|
C,G
|
|
MHBD deficiency
|
Avoid fasting, sick day management,
isoleucine restricted diet
|
5
|
Standard of care
|
C
|
|
mHMG-CoA synthase deficiency
|
Avoid fasting,sick day management,
+/−dietary precursor restriction
|
5
|
Standard of care
|
C
|
|
Molybdenum co-factor deficiency type
A
|
Precursor Z/cPMP
|
4
|
Individual basis
|
A,F
|
[25
|
l.o. MTHFR deficiency
|
Betaine supplements, +/−folate,
carnitine, methionine supplements
|
4
|
Standard of care
|
C,D,G
|
|
Niemann–Pick disease type C
|
Miglustat
|
1b
|
Standard of care
|
D,E
|
|
l.o. OTC deficiency
|
Dietary protein restriction,
citrulline supplements, Sodium benzoate/phenylbutyrate (Liver
transplantation)
|
2b & 4
|
Standard of care (Individual basis)
|
B,C,D,E,F,G (C)
|
|
PCD deficiency
|
BH4
|
4
|
Standard of care
|
A,E
|
[91
|
PDH complex deficiency
|
Ketogenic diet & thiamine
|
4
|
Individual basis
|
D,E,F
|
[122
|
Phenylketonuria
|
Dietary phenylalanine restriction
+/−amino-acid supplements (BH(4) supplement)
|
2a (4)
|
Standard of care (Individual basis)
|
B, D, E (C)
|
|
PHGDH deficiency
|
L-serine & +/−glycine supplements
|
4
|
Standard of care
|
D,F
|
|
PSAT deficiency
|
L-serine & +/−glycine supplements
|
4
|
Standard of care
|
D,F
|
|
l.o. Propionic acidemia
|
Dietary protein restriction,
carnitine supplements, avoid fasting, sick day management
|
2c
|
Standard of care
|
C,G
|
|
PSPH deficiency
|
L-serine & +/−glycine supplements
|
4
|
Standard of care
|
D,F
|
|
PTPS deficiency
|
BH4, diet, amine replacement
|
4
|
Standard of care
|
A,E
|
[91
|
Pyridoxine dependent epilepsy
|
Pyridoxine
|
4
|
Standard of care
|
A,F
|
|
Pyrimidine 5-nucleotidase
superactivity
|
Uridine supplements
|
1b
|
Standard of care
|
A,B,F,G
|
[129
|
Sanfilippo syndrome A (MPS IIIa)
|
Haematopoietic stem cell
transplantation
|
4–5
|
Individual basis
|
D
|
|
Sanfilippo syndrome B (MPS IIIb)
|
Haematopoietic stem cell
transplantation
|
4–5
|
Individual basis
|
D
|
|
Sanfilippo syndrome C (MPS IIIc)
|
Haematopoietic Stemcell Transplantation
|
4–5
|
Individual Basis
|
D
|
|
Sanfilippo syndrome D (MPS IIId)
|
Haematopoietic stem cell
transplantation
|
4–5
|
Individual basis
|
D
|
|
SCOT deficiency
|
Avoid fasting, protein restriction,
sick day management
|
5
|
Standard of care
|
C
|
[65
|
Sjögren–Larsson syndrome
|
Diet: low fat, medium chain &
essential fatty acid supplements & Zileuton
|
5
|
Individual basis
|
D,G
|
|
Sly syndrome (MPS VII)
|
Haematopoietic stem cell
transplantation
|
4-5
|
Individual basis
|
D
|
|
Smith–Lemli–Opitz syndrome
|
Cholesterol & simvastatin
|
4–5
|
Individual basis
|
B,D
|
|
SPR deficiency
|
Amine replacement
|
4
|
Standard of care
|
A,E
|
[134
|
SSADH deficiency
|
Vigabatrin
|
4
|
Individual basis
|
B,F
|
[135
|
Thiamine-responsive encephalopathy
|
Thiamin supplement
|
4-5
|
Standard of care
|
E
|
|
Tyrosine hydroxylase deficiency
|
L-dopa substitution
|
4
|
Standard of care
|
A,E
|
[138
|
Tyrosinemia type II
|
Dietary phenylalanine & tyrosine
restriction
|
4-5
|
Standard of care
|
D,G
|
|
Wilson disease
|
Zinc & tetrathiomolybdate
|
1b
|
Standard of care
|
E,G
|
developmental disorder:
Diagnostic algorithm for identification of treatable causes and new digital resource
Table 2aOverview of the first tier metabolic screening tests denoting
all diseases (with OMIM# and gene(s)) potentially identified per individual
test.
|
|||
Diagnostic test
|
Disease
|
OMIM#
|
Gene
|
Blood tests
|
|||
Plasma amino acids
|
l.o. Argininemia
|
ARG1 (AR)
|
|
Plasma amino acids
|
l.o. Argininosuccinic aciduria
|
ASL (AR)
|
|
Plasma amino acids
|
l.o. Citrullinemia
|
ASS1 (AR)
|
|
Plasma amino acids
|
Citrullinemia type II
|
SLC25A13 (AR)
|
|
Plasma amino acids
|
l.o. CPS deficiency
|
CPS1 (AR)
|
|
Plasma amino acids
|
HHH syndrome (hyperornithinemia,
hyperammonemia, homocitrullinuria)
|
SLC25A15 (AR)
|
|
Plasma amino acids
|
Maple syrup urine disease (variant)
|
BCKDHA/BCKDHB/DBT(AR)
|
|
Plasma amino acids
|
l.o. NAGS deficiency
|
NAGS (AR)
|
|
Plasma amino acids (& UOA incl
orotic acid)
|
l.o. OTC deficiency
|
OTC (X-linked)
|
|
Plasma amino acids
|
Phenylketonuria
|
PAH (AR)
|
|
Plasma amino acids (& UOA)
|
Tyrosinemia type II
|
TAT (AR)
|
|
Plasma amino acids (tHcy)
|
l.o. MTHFR deficiency
|
MTHFR (AR)
|
|
Plasma total homocysteine
|
Cobalamin E deficiency
|
MTRR (AR)
|
|
Plasma total homocysteine
|
Cobalamin G deficiency
|
MTR (AR)
|
|
Plasma total homocysteine (& UOA)
|
Cobalamin F deficiency
|
LMBRD1 (AR)
|
|
Plasma total homocysteine (& OUA)
|
Cobalamin C deficiency
|
MMACHC (AR)
|
|
Plasma total homocysteine (& OUA)
|
Homocystinuria
|
CBS (AR)
|
|
Plasma total homocysteine (& PAA)
|
l.o. MTHFR deficiency
|
MTHFR (AR)
|
|
Plasma total homocysteine (& UOA)
|
Cobalamin D deficiency
|
MMADHC (AR)
|
|
Serum ceruloplasmin & copper
(& serum iron & ferritin)
|
Aceruloplasminemia
|
CP (AR)
|
|
Serum copper & ceruloplasmin
(& urine copper)
|
MEDNIK diseases
|
AP1S1 (AR)
|
|
Serum copper & ceruloplasmin
(urine deoxypyridonoline)
|
Menkes disease/occipital horn
syndrome
|
ATP7A (AR)
|
|
Serum copper & ceruloplasmin
(& urine copper)
|
Wilson disease
|
ATP7B (AR)
|
|
Urine tests
|
|||
Urine creatine metabolites
|
AGAT deficiency
|
GATM (AR)
|
|
Urine creatine metabolites
|
Creatine transporter defect
|
SLC6A8 (X-linked)
|
|
Urine creatine metabolites
|
GAMT deficiency
|
GAMT (AR)
|
|
Urine glycosaminoglycans
|
Hunter syndrome (MPS II)
|
IDS (X-linked)
|
|
Urine glycosaminoglycans
|
Hurler syndrome (MPS I)
|
IDUA (AR)
|
|
Urine glycosaminoglycans
|
Sanfilippo syndrome A (MPS IIIa)
|
SGSH (AR)
|
|
Urine glycosaminoglycans
|
Sanfilippo syndrome B (MPS IIIb)
|
NAGLU (AR)
|
|
Urine glycosaminoglycans
|
Sanfilippo syndrome C (MPS IIIc)
|
HGSNAT (AR)
|
|
Urine glycosaminoglycans
|
Sanfilippo syndrome D (MPS IIId)
|
GNS (AR)
|
|
Urine glycosaminoglycans
|
Sly syndrome (MPS VII)
|
GUSB (AR)
|
|
Urine oligosaccharides
|
α-Mannosidosis
|
MAN2B1 (AR)
|
|
Urine oligosaccharides
|
Aspartylglucosaminuria
|
AGA (AR)
|
|
Urine organic acids
|
β-Ketothiolase deficiency
|
ACAT1 (AR)
|
|
Urine organic acids
|
Cobalamin A deficiency
|
MMAA (AR)
|
|
Urine organic acids
|
Cobalamin B deficiency
|
MMAB (AR)
|
|
Urine organic acids
|
l.o. Glutaric acidemia I
|
GCDH (AR)
|
|
Urine organic acids
|
Glutaric acidemia II
|
ETFA, ETFB, ETFDH(AR)
|
|
Urine organic acids
|
HMG-CoA lyase deficiency
|
HMGCL (AR)
|
|
Urine organic acids
|
Holocarboxylase synthetase deficiency
|
HLCS (AR)
|
|
Urine organic acids
|
3-Methylglutaconic aciduria type I
|
AUH (AR)
|
|
Urine organic acids
|
MHBD deficiency
|
HSD17B10 (X-linked
recessive)
|
|
Urine organic acids
|
mHMG-CoA synthase deficiency
|
HMGCS2 (AR)
|
|
Urine organic acids
|
SCOT deficiency
|
OXCT1 (AR)
|
|
Urine organic acids
|
SSADH deficiency
|
ALDH5A1 (AR)
|
|
Urine organic acids (& ACP)
|
Ethylmalonic encephalopathy
|
ETHE1 (AR)
|
|
Urine organic acids (& ACP)
|
l.o. Isovaleric acidemia
|
IVD (AR)
|
|
Urine organic acids (& ACP)
|
3-Methylcrotonylglycinuria
|
MCC1/MCC2 (AR)
|
|
Urine organic acids (& ACP)
|
l.o. Methylmalonic acidemia
|
MUT (AR)
|
|
Urine organic acids (& tHcy)
|
Cobalamin C deficiency
|
MMACHC (AR)
|
|
Urine organic acids (& tHcy)
|
Cobalamin D deficiency
|
MMADHC (AR)
|
|
Urine organic acids (& tHcy)
|
Homocystinuria
|
CBS (AR)
|
|
Urine organic acids incl orotic acid
(& PAA)
|
l.o. OTC deficiency
|
OTC (X-linked)
|
|
Urine organic acids (& PAA)
|
Tyrosinemia type II
|
TAT (AR)
|
|
Urine organic acids (& ACP)
|
l.o. Propionic acidemia
|
PCCA/PCCB (AR)
|
|
Urine organic acids (tHcy)
|
Cobalamin F deficiency
|
LMBRD1 (AR)
|
|
Urine purines & pyrimidines
|
Lesch–Nyhan syndrome
|
HPRT (AR)
|
|
Urine purines & pyrimidines
|
Molybdenum cofactor deficiency type A
|
MOCS1, MOCS2, (AR)
|
|
Urine purines & pyrimidines
|
Pyrimidine 5-nucleotidase
superactivity
|
NT5C3 (AR)
|
Table 2bOverview of all diseases (in alphabetical order) requiring
second tier biochemical testing, i.e. a specific test per disease approach;
for each disease the OMIM# and gene(s) are listed.
|
|||
Disease
|
OMIM#
|
Gene(s)
|
Diagnostic test
|
(X-linked) Adrenoleukodystrophy
|
ABCD1 (X-linked)
|
Plasma very long chain fatty acids
|
|
Biotin responsive basal ganglia
disease
|
SLC19A3 (AR)
|
Gene analysis
|
|
Biotinidase deficiency
|
BTD (AR)
|
Biotinidase enzyme activity
|
|
Cerebral folate receptor-α deficiency
|
FOLR1 (AR)
|
CSF 5′-methyltetrahydrofolate
|
|
Cerebrotendinous xanthomatosis
|
CYP27A1 (AR)
|
Plasma cholestanol
|
|
Co-enzyme Q10 deficiency
|
COQ2, APTX, PDSS1,PDSS2, CABC1, COQ9(most AR)
|
Co-enzyme Q (fibroblasts) & gene
analysis
|
|
Congenital intrinsic factor
deficiency
|
GIF (AR)
|
Plasma vitamin B12 & folate
|
|
Dihydrofolate reductase deficiency
|
DHFR (AR)
|
CSF 5′-methyltetrahydrofolate
|
|
DHPR deficiency (biopterin
deficiency)
|
QDPR (AR)
|
CSF neurotransmitters & biopterin
loading test
|
|
Gaucher disease type III
|
GBA (AR)
|
Glucocerebrosidase enzyme activity
(lymphocytes)
|
|
GLUT1 deficiency syndrome
|
SLC2A1 (AR)
|
CSF: plasma glucose ratio
|
|
GTPCH1 deficiency
|
GCH1 (AR)
|
CSF neurotransmitters & biopterin
loading test
|
|
Hypermanganesemia with dystonia,
polycythemia, and cirrhosis (HMDPC)
|
SLC30A10
|
Whole blood manganese
|
|
Hyperinsulinism hyperammonemia
syndrome
|
GLUD1 (AR)
|
Gene analysis (& ammonia,
glucose, insulin)
|
|
Imerslund Gräsbeck syndrome
|
CUBN & AMN (AR)
|
Plasma vitamin B12 & folate
|
|
MELAS
|
MTTL1, MTTQ, MTTH,MTTK, MTTC, MTTS1,MTND1, MTND5, MTND6,MTTS2 (Mt)
|
Mitochondrial DNA mutation testing
|
|
l.o. Metachromatic leukodystrophy
|
ARSA (AR)
|
Arylsulfatase-α enzyme activity
|
|
Niemann–Pick disease type C
|
NPC1 NPC2 (AR)
|
Filipin staining test (fibroblasts)
& gene analyses
|
|
l.o. Non-ketotic hyperglycinemia
|
AMT/GLDC/GCSH (AR)
|
CSF amino acids (& PAA)
|
|
PCBD deficiency (biopterin deficiency)
|
PCBD1 (AR)
|
CSF neurotransmitters & biopterin
loading test
|
|
PDH complex deficiency
|
PDHA1 (X-linked), DLAT(AR), PDHX (AR)
|
Serum & CSF lactate:pyruvate
ratio enzyme activity, gene analysis
|
|
PHGDH deficiency (serine deficiency)
|
PHGDH (AR)
|
CSF amino acids (& PAA)
|
|
PSAT deficiency (serine deficiency)
|
PSAT1 (AR)
|
CSF amino acids (& PAA)
|
|
PSPH deficiency (serine deficiency)
|
PSPH (AR)
|
CSF amino acids (& PAA)
|
|
PTS deficiency (biopterin deficiency)
|
PTS (AR)
|
CSF neurotransmitters & biopterin
loading test
|
|
Pyridoxine dependent epilepsy
|
ALDH7A1 (AR)
|
Urine α-aminoadipic semialdehyde
& plasma pipecolic acid
|
|
Sjögren Larsson syndrome
|
ALDH3A2 (AR)
|
Fatty aldehyde dehydrogenase enzyme
activity
|
|
Smith Lemli Opitz syndrome
|
DHCR7 (AR)
|
Plasma
7-dehydrocholesterol:cholesterol ratio
|
|
SPR deficiency (biopterin deficiency)
|
SPR (AR)
|
CSF neurotransmitters, biopterin
& Phe loading test (enzyme activity, gene analysis)
|
|
Thiamine responsive encephalopathy
|
SLC19A3 (AR)
|
Gene analysis
|
|
Tyrosine hydroxylase deficiency
|
TH (AR)
|
CSF neurotransmitters, gene analysis
|
|
VMAT2 deficiency
|
SLC18A2 (AR)
|
Urine mono-amine metabolites
|
At BC Children's hospital with an autism diagnosis you get a "microarray" test - which I don't think is the whole genome sequencing, but maybe I am wrong? My daughters microarray came back as normal (from BC Children's). I am not sure how I would find out if they tested for all of the above.
ReplyDeleteMicroarray is just one kind of genetic test. Whole genome sequencing costs about $1,000 at UBC and it is for research purposes in theory. All the tests for those 81 disorders are available, but I doubt you get them, without asking/paying. Many syndromes have physical signs that should alert the physician and then they should investigate.
ReplyDeleteThank you Peter this is good to know and I will contact BC Children's to confirm is I can get it done - in Canada things are tricky as they won't let you order certain tests even if you are willing to pay privately. I contacted GeneDX as they do whole genome and they have a new Autism ID Panel in which they also test parents. Here is more info directly from them:
ReplyDelete"We have a relatively new test called the Autism/ID Xpanded Panel. This is focused more on sequence variants rather than copy number variants. It uses exome sequencing to look at 2000 genes that have been associated with autism and/or intellectual disability. We run this on samples from the proband and the parents at the same time. Including the parents in the analysis means we can look directly at the inheritance of a variant to try to determine its significance. This is currently $5000 USD"
I have been reading the same papers wondering if UBC approach is suitable in autism. It has been developed for ID, but there’s a story of a boy with autism as his main diagnosis and severe SIBs, enrolled into TIDE-BC and diagnosed with neurometabolic condition at the age of 16(!), who improved on proper treatment:
ReplyDeletehttp://www.tidebc.org/pa/Jake/
Detailed testing for inborn errors of metabolism is not something for ‘do it yourself’ way and if you don’t live in Vancouver, Arkansas or Thessaloniki you are perhaps in a neurometabolic desert re autism. It is the tertiary reference center for IEMs in my country where I was told to ‘lower my expectations and accept disability’. So: is it possible to develop a list of screening tests for IEMs in autism available for parents who do not want to lower their expectations or wait 16 years?
Fig. 1 in the second paper presents the “two-tiered algorithm for diagnosis of treatable IEMs in IDD. The first tier testing comprises group metabolic tests in urine and blood which should be performed in every patient with IDD of unknown cause.” Maybe the first tier should be considered in autism as well? At time of first symptoms suggesting ID, in non-responders, severe end of spectrum or even for all at time of ASD diagnosis if early established?
These screening tests are:
Blood: ammonia, lactate, plasma amino acids, total homocysteine, acylcarnitine profile, copper, ceruloplasmin.
Urine: organic acids, purines and pyrimidines, creatine metabolites, oligosaccharides, glycosaminoglycans.
Most can be done in my local lab or elsewhere sending the samples.
In case of abnormal results one can insist on further evaluation.
Also there is a relevant case report by the team of Prof. Evangeliou:
https://www.ncbi.nlm.nih.gov/pubmed/26806207
“Succinic Semialdehyde Dehydrogenase Deficiency Presenting as Autism Spectrum Disorder”
Table 1 lists: “Inborn errors of metabolism with autism phenotype as the main or only symptom”.
Or is just WES enough?
What do you think?
Genetic testing is not a mature science. You definitely need the Whole genome not just the exome and even then there are lots of false negatives. When they know where to look they find dysfunctions, but when looking at the entire genome they miss things. This means you can pay lots of money and think you have covered all possible errors when you have not.
DeleteSo measuring specific biological markers in the lab still has great merit. The problem is that sometimes there are no reliable markers.
Hi Peter and all,
DeletePlease bear with me for the long post.
We consulted Dr.Rossignol and he recommended Creon, Oxytocin nasal spray, Sulforaphane, L thianine, L taurine and leucovorin immediately after consultation.
Also we did the following tests and got results.
24 hour EEG with video monitoring
Comprehensive stool analysis/parasitology X3 (Doctors data lab)
Urine microbial organic acid test (Great plains lab)
Blood test:
Amino acids plasma
Comprehensive metabolic panel
IGE total
CRP
ANA
ASO titer
Anti DNAse-B
CBC with automated Diff
TSH, FT3, FT4
Total cholesterol
Carnitine and Acyl Carnitine profile
Ferritin, Lead, 25 Hydroxy vitamin D, Zinc, Magnesium
AM Cortisol, DHEA Sulphate, testosterone
Homocysteine
Uric acid serum
IGF-1
MMR, DPT and Polio titer
Fragile X (AWAITING RESULT)
Except Ferritin, vitamin D, Zinc and total cholesterol (for which we will start supplements) all are normal. Few negligible red marks in plasma amino acid. Dr.Rossignol said that CSF can give conclusive ideas but patient is very young and so let us proceed slowly. Let us do the supplements for the next 3 months, give MB12 shots daily (now alternative days) reach optimum level of leucovorin and then we will review.
We asked whether Whole genome sequencing or Chromosomal microarray will give ideas, he was non-committal saying that not only these tests are expensive but without good interpretation they are of no use. What about SPECT or MRI? He said EEG is normal and we would treat based on that. However it is optional. We asked any other tests that will give conclusive ideas he said that ‘Laboratoire Philppe Auguste’ does some tests. That might help.
http://labbio.sectolink.org/index.php?page=contact
Any idea about this lab and the tests?
Will TH1 and TH2 profile give any ideas? Immunologist and/or endocrinologist may help? They will come to India for the Christmas holidays. Lab tests and Doctor fees will be cost-effective here.
Oxytocin, L-theanine, L-taurine and sulforaphane show no response. His anxiety (mixed with fear and panic, more like separation anxiety) and irritability remain the same. No improvement in awareness and communication. 5mg X2 bumetanide for 40 days had no effect. However we have now got 1mg tablets we will try in the near future. As we have started with leucovorin we have to reach 20mg level. By the by leucovorin makes him more irritable and unmanagable so we tried GABA supplement and it makes him calmer. Does it mean bumetanide will not be effective?
Once again, sorry for the long post. Thank you.
That is a lot of tests. I am not sure of their value or the ones from the lab in France.
DeleteIt appears that a negative reaction to leucoverin is quite common, that might suggest it is unwise to continue.
Bumetanide will either help within a few weeks or be of no value. If he does not respond then it is not for him.
Thank you Roger and Peter for reply.
ReplyDeleteThere’s another paper by TIDE-BC team on WES and management of neurometabolic disorders:
https://www.ncbi.nlm.nih.gov/pubmed/27276562
"We obtained a diagnosis in 28 of 41 probands (68%) who were evaluated. A test of a targeted intervention was performed in 18 patients (44%)."
I think this is great result and it’s important that they combined WES with detailed clinical analysis and metabolic biomarkers.
There were children with autism among them:
“An example from this study was an 8-year-old boy with intellectual developmental disorder, autism, movement disorder, intractable epileptic encephalopathy, and persistently abnormal neurotransmitter profiles [...] in whom we identified a de novo pathogenic splice-site variant. This mutation resulted in the deletion of exon 14 in SCN2A, encoding voltage gated sodium channel type II. [...] We hypothesized that this channelopathy causes abnormal synaptic secretion and uptake of monoamine metabolites through impaired vesicular release and imbalance in electrochemical ion gradients, which in turn aggravate the seizures.Treatment with oral 5-hydroxytryptophan, levodopa, carbidopa, and a dopa agonist normalized the child’s levels of neurotransmitters in the cerebrospinal fluid and was associated with improvements in attention, communication, and seizure control."
My question was about screening for neurometabolic conditions in autism that parents could do on their own and in case of positive result look for further evaluation (as simple, cheap and sensitive as possible).
I don't know if this topic has been discussed before...
ReplyDeletemy almost 12 year old son has I think reached puberty. and is engaged is mastabatory behaviour a lot!!! Is there anything I can give him to reduce this compulsion? while I know that it's very common age wise,I think I need to address this. He is very high functioning and completely verbal. thoughts? ideas? thanks!
Debbie, you might want to talk to a behavioral specialist. Being so high functioning, your son likely never had one.
DeleteOne such person is Peter Gerhardt, who writes a lot about this subject, but any experienced ABA consultant can advise you.
http://search.naric.com/research/rehab/documents/O19258%20-%20Power%20Point.pdf
It is not a medical or biological problem. it is a behavioral issue.
Thanks for your prompt reply.
DeleteDo you really think this is purely behavioural?
B/c I think if he didn't feel the urge to seek out this pleasurable sensation, then he wouldn't be feeling the need to masterbate; does that make any sense? Thanks
Debbie, find an older ABA behavioral consultant who will have seen hundreds of boys passing puberty. He/she will tell you about all the various issues that can arise and how to deal with them. Having had that discussion you will feel better about your son's behavior and how to guide it. Our own ABA consultant gave us advice a while back even without us asking for it, so it must be a regular issue that comes up.
DeleteRoger,
ReplyDeleteWhen they did WES for you, they were looking specifically for something based on your biomarkers or they looked generally for each and every mutation? What is the normal procedure? Thank you.
Hi Peter,
ReplyDeleteHave you heard or read about the MSSNG study through Sick Kids hospital in Toronto, Canada? They are completing Whole Genome Sequencing on 10,000 families worldwide, and on the Sick Kids Hospital website there is a few pages about how this test should be offered instead of the microarray to every diagnosed child as it picks up more info then the standard microarray. Here is the info: https://www.mss.ng/about
It is interesting and the more high quality data available the better.
DeleteThere is a lab in the states that charges $299 for a Whole Genome Sequencing. Nebula Genomics.
ReplyDelete